Archive for the ‘Ionis Pharmaceuticals’ Category

Ionis Pharmaceuticals

January 25th, 2016 | Posted in 2016, Ionis Pharmaceuticals, Isis Pharmaceuticals

Ionis Pharmaceuticals, formerly Isis Pharmaceuticals, has been granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington’s disease. The Orphan Drug Designation entitles the company to seven years of market exclusivity in the U.S. if the drug candidate reaches the market. The designation is part of the Orphan Drug Act, which provides […]

Ionis Pharmaceuticals

December 22nd, 2015 | Posted in 2015, Ionis Pharmaceuticals, Isis Pharmaceuticals

Carlsbad-based Isis Pharmaceuticals is changing its name to Ionis Pharmaceuticals. The company is also changing its Nasdaq stock symbol from ISIS to IONS, and its website address to www.ionispharma.com. While it didn’t spell out the reason for the name change, ISIS is also the acronym for Islamic State of Iraq and al-Sham, an Islamic fundamentalist terrorist group. […]